第 4 周的血浆利巴韦林谷浓度可预测接受慢性丙型肝炎治疗的 HIV/HCV 合并感染患者的丙型肝炎病毒（HCV）复发。
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
机构信息
Laboratory of Pharmacology, Hospital Carlos III, 28029 Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2010 Apr;54(4):1647-9. doi: 10.1128/AAC.01399-09. Epub 2010 Jan 25.
Abstract
The influence of ribavirin trough concentrations (RBV C(trough)) on the risk of hepatitis C virus (HCV) relapse was retrospectively analyzed in 99 HIV-HCV-coinfected patients who achieved end-of-treatment response with pegylated alpha interferon plus weight-based RBV. The independent predictors (odds ratio [OR] [95% confidence interval (CI)]) of HCV relapse were RBV plasma C(trough) of <2.5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse.
摘要
回顾性分析了 99 例接受聚乙二醇干扰素α联合基于体重的利巴韦林治疗并获得治疗结束时应答的 HIV-HCV 共感染患者，分析利巴韦林谷浓度（RBV C(trough))对丙型肝炎病毒（HCV）复发风险的影响。HCV 复发的独立预测因子（比值比[OR] [95%置信区间（CI)]）为 RBV 血浆 C(trough) <2.5μg/ml（4.5 [1.3 至 15.5]）、基线血清 HCV RNA（2.5 [1.2 至 5.1]）和 HCV 基因型 1 或 4（13.3 [2.6 至 66.7]）。监测 RBV C(trough) 可能有助于早期调整 RBV 剂量以避免 HCV 复发。
相似文献
1
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.第 4 周的血浆利巴韦林谷浓度可预测接受慢性丙型肝炎治疗的 HIV/HCV 合并感染患者的丙型肝炎病毒（HCV）复发。
Antimicrob Agents Chemother. 2010 Apr;54(4):1647-9. doi: 10.1128/AAC.01399-09. Epub 2010 Jan 25.
2
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.基线血清丙型肝炎病毒（HCV）RNA水平及治疗第4周时的反应，是HIV/HCV合并感染患者接受聚乙二醇干扰素联合利巴韦林治疗后复发的最佳预测指标。
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. doi: 10.1097/QAI.0b013e318061b5d9.
3
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.治疗慢性丙型肝炎病毒（HCV）的疗效及影响因素分析：HIV/HCV 合并感染患者经治后复发或无应答的再治疗
J Acquir Immune Defic Syndr. 2010 Mar;53(3):364-8. doi: 10.1097/QAI.0b013e3181bd5ce1.
4
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.比较高剂量利巴韦林诱导与标准利巴韦林剂量联合聚乙二醇干扰素-α治疗 HIV 感染患者慢性丙型肝炎：PERICO 试验。
J Infect Dis. 2012 Sep 15;206(6):961-8. doi: 10.1093/infdis/jis449. Epub 2012 Jul 17.
5
6
7
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.聚乙二醇干扰素联合利巴韦林加硝唑尼特对丙型肝炎病毒4型与人类免疫缺陷病毒合并感染的疗效欠佳。
PLoS One. 2015 Dec 7;10(12):e0143492. doi: 10.1371/journal.pone.0143492. eCollection 2015.
8
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.聚乙二醇干扰素联合利巴韦林治疗4型基因所致慢性丙型肝炎HIV感染患者的疗效
J Viral Hepat. 2008 Oct;15(10):710-5. doi: 10.1111/j.1365-2893.2008.01015.x. Epub 2008 Jul 10.
9
10
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.在瑞士HIV队列研究中，利巴韦林浓度无法预测接受利巴韦林和聚乙二醇化干扰素治疗的HIV/HCV合并感染患者的持续病毒学应答。
PLoS One. 2015 Jul 28;10(7):e0133879. doi: 10.1371/journal.pone.0133879. eCollection 2015.
引用本文的文献
1
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.在瑞士HIV队列研究中，利巴韦林浓度无法预测接受利巴韦林和聚乙二醇化干扰素治疗的HIV/HCV合并感染患者的持续病毒学应答。
PLoS One. 2015 Jul 28;10(7):e0133879. doi: 10.1371/journal.pone.0133879. eCollection 2015.
2
A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.利巴韦林的药理学特征及其在慢性丙型肝炎感染中的血药浓度监测
J Clin Exp Hepatol. 2012 Mar;2(1):42-54. doi: 10.1016/S0973-6883(12)60090-5. Epub 2012 Apr 12.
3
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir.对达卡他韦联合阿舒瑞韦耐药的丙型肝炎病毒1b型感染患者再治疗方案的体外评估
Infect Dis Ther. 2014 Dec 17;4(1):137-44. doi: 10.1007/s40121-014-0052-8.
4
[Not Available].[无可用内容]
Can J Infect Dis Med Microbiol. 2014 Spring;25(1):39-62. doi: 10.1155/2014/921314.
5
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.加拿大健康研究院加拿大艾滋病毒试验网合并感染与合并疾病核心：加拿大成人 HIV/丙型肝炎合并感染管理与治疗指南。
Can J Infect Dis Med Microbiol. 2013 Winter;24(4):217-38. doi: 10.1155/2013/781410.
6
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.多重液相色谱-串联质谱法同时测定利巴韦林、博赛泼维及特拉匹韦的治疗药物浓度。
Antimicrob Agents Chemother. 2013 Jul;57(7):3147-58. doi: 10.1128/AAC.00281-13. Epub 2013 Apr 29.
7
Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.药剂师在关爱艾滋病毒/艾滋病患者中的作用：临床实践指南
Can J Hosp Pharm. 2012 Mar;65(2):125-45. doi: 10.4212/cjhp.v65i2.1120.
本文引用的文献
1
The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.利巴韦林治疗药物监测在慢性丙型肝炎患者中的应用——一项关键性评价。
Ann Pharmacother. 2009 Dec;43(12):2044-63. doi: 10.1345/aph.1M225. Epub 2009 Nov 17.
2
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.利巴韦林血浆浓度可预测既往接受治疗的丙型肝炎病毒与人类免疫缺陷病毒合并感染患者对聚乙二醇干扰素α-2a联合利巴韦林治疗的持续病毒学应答。
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):428-30. doi: 10.1097/QAI.0b013e3181b62858.
3
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.特拉匹韦与聚乙二醇干扰素联合或不联合利巴韦林用于慢性丙型肝炎病毒感染的治疗。
N Engl J Med. 2009 Apr 30;360(18):1839-50. doi: 10.1056/NEJMoa0807650.
4
Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.监测利巴韦林血药浓度对改善慢性丙型肝炎患者治疗反应的有效性
J Antimicrob Chemother. 2008 Dec;62(6):1174-80. doi: 10.1093/jac/dkn421. Epub 2008 Oct 17.
5
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.聚乙二醇化干扰素联合利巴韦林治疗在接受阿巴卡韦加拉米夫定或替诺福韦加拉米夫定或恩曲他滨作为核苷类似物主干治疗的HIV/丙型肝炎病毒合并感染患者中的疗效。
J Antimicrob Chemother. 2008 Dec;62(6):1365-73. doi: 10.1093/jac/dkn420. Epub 2008 Oct 13.
6
7
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.利用利巴韦林谷浓度预测接受利巴韦林和聚乙二醇干扰素治疗的HIV/HCV合并感染患者的持续病毒学应答和血液学毒性。
J Antimicrob Chemother. 2008 Apr;61(4):919-24. doi: 10.1093/jac/dkn013. Epub 2008 Jan 31.
8
Rapid virologic response: a new milestone in the management of chronic hepatitis C.快速病毒学应答：慢性丙型肝炎治疗的一个新里程碑。
Clin Infect Dis. 2008 Jan 1;46(1):78-84. doi: 10.1086/523585.
9
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.丙型肝炎基因1型患者的个体化治疗疗程：一项随机对照试验。
Hepatology. 2008 Jan;47(1):43-50. doi: 10.1002/hep.22061.
10
Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.采用新型固相萃取法通过高效液相色谱法测定接受慢性丙型肝炎治疗患者的利巴韦林血浆浓度。
Ther Drug Monit. 2007 Dec;29(6):802-6. doi: 10.1097/FTD.0b013e31815bddf3.
Zotero 插件